Department of Oncology, Ina Central Hospital, 1313-1 Koshiro-kubo, Ina, Nagano, 396-8555, Japan.
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
J Cancer Surviv. 2023 Jun;17(3):781-794. doi: 10.1007/s11764-022-01250-8. Epub 2022 Sep 1.
Although rather favorable probabilities of return to work have been reported after allogeneic hematopoietic cell transplantation (allo-HCT), survivors often have difficulty continuing to work because of their immunocompromised status and diverse late effects after allo-HCT. We evaluated the incidence of and risk factors for recurrent sick leave in allo-HCT survivors after they initially returned to work.
We targeted allo-HCT survivors who were employed at diagnosis, aged 20-64 at survey, and survived for ≥ 2 years without relapse. Of the 1904 survivors who were informed of the study, 1148 returned the questionnaire (60%), and 1048 eligible participants were included in the overall analysis. In the present study that considered recurrent sick leave after return to work, we targeted 896 participants who returned to work at least once after allo-HCT. Participants stated if they had recurrent sick leave after returning to work and its reasons, as well as associated patient-, HCT/HCT center-, and work-related factors and clinical events after allo-HCT. A logistic regression analysis was conducted to explore correlated factors for recurrent sick leave.
In survivors who returned to work, 30% required recurrent sick leave. The most frequent causes of recurrent leave were physical issues (72%), and analysis of free descriptions demonstrated that these were mainly associated with graft-versus-host disease, infection, or readmission. Other reasons included work-related issues such as gap between physical and working conditions. Multivariate analysis showed that cord blood transplantation, longer employment duration, and counseling from healthcare professionals were associated with a lower risk of recurrent leave. Readmission, immunosuppressant use, and symptoms involving the respiratory system, gut, and joints and muscles were associated with a higher risk.
Our results drawn from a large cohort study should help healthcare professionals identify and assist at-risk patients. Multi-professional teams that provide continuous support and effective communication with the workplace are necessary to improve long-term outcomes after allo-HCT.
In order to continue working after the initial return to work, it is important to receive counseling from healthcare professionals and obtain reasonable accommodation from workplace.
虽然异基因造血细胞移植(allo-HCT)后报告的工作恢复可能性相当有利,但由于免疫功能低下和 allo-HCT 后多种晚期效应,幸存者往往难以继续工作。我们评估了 allo-HCT 幸存者最初返回工作岗位后再次请病假的发生率和危险因素。
我们将目标锁定在诊断时就业、调查时年龄在 20-64 岁且在无复发的情况下存活至少 2 年的 allo-HCT 幸存者身上。在通知参加研究的 1904 名幸存者中,有 1148 人返回了问卷(60%),并对 1048 名符合条件的参与者进行了总体分析。在这项考虑 allo-HCT 后重返工作岗位后再次请病假的研究中,我们将目标锁定在至少一次返回 allo-HCT 后重返工作岗位的 896 名参与者身上。参与者陈述了他们在返回工作岗位后是否再次请病假以及请病假的原因,以及 allo-HCT 后与患者、HCT/HCT 中心和工作相关的因素和临床事件相关的因素。进行逻辑回归分析以探讨再次请病假的相关因素。
在返回工作岗位的幸存者中,有 30%需要再次请病假。再次请病假最常见的原因是身体问题(72%),对自由描述的分析表明,这些主要与移植物抗宿主病、感染或再入院有关。其他原因包括与工作相关的问题,例如身体和工作条件之间的差距。多变量分析表明,脐带血移植、更长的就业时间和医护人员的咨询与较低的再休假风险相关。再入院、免疫抑制剂的使用以及涉及呼吸系统、肠道和关节肌肉的症状与较高的风险相关。
我们从大型队列研究中得出的结果应有助于医疗保健专业人员识别和帮助高危患者。需要多专业团队提供持续支持和与工作场所进行有效沟通,以改善 allo-HCT 后的长期结果。
为了在最初返回工作后继续工作,从医护人员那里获得咨询并从工作场所获得合理的适应是很重要的。